Review: The therapeutic role of RAS blockade in chronic heart failure

  title={Review: The therapeutic role of RAS blockade in chronic heart failure},
  author={Christian Werner and Michael B{\"o}hm},
  journal={Therapeutic Advances in Cardiovascular Disease},
  pages={167 - 177}
  • C. Werner, M. Böhm
  • Published 1 June 2008
  • Biology, Medicine
  • Therapeutic Advances in Cardiovascular Disease
Cardiovascular disease represents a continuum that starts with risk factors such as hypertension and progresses to atherosclerosis, end-organ damage, and ultimately to chronic heart failure (CHF) and premature death. Renin-angiotensin system (RAS) blockade with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II type 1 receptor blockers (ARBs) has turned out to be beneficial at all stages of this continuum. Several mechanisms govern the progression of structural myocardial… 

Figures and Tables from this paper

Review Article: Management of Subclinical Ventricular Dysfunction

Early identification of ALVD through screening is of paramount importance and control of risk factors and comorbid conditions could slow down progression to overt heart failure.

ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease

The role mono- and combined therapy of ACE inhibitors and angiotensin II receptor antagonists play in ischemic heart disease is summarized to improve ideas for developing new formulations with combinations of these drugs in the future.

Renin-angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure.

PVAT is suggested as a target in the pathophysiology of vascular dysfunction in HF and new perspectives for the treatment of this syndrome are provided.

Diabetic cardiomyopathy: ongoing controversies in 2012

There is no specific treatment of diabetic cardiomyopathy that targets its pathophysiological substrate, but various therapeutic options are discussed that include improving diabetic control with both diet and drugs (metformin and thiazolidinediones), the use of ACE inhibitors, beta blockers, and calcium channel blockers.

Local angiotensin II aggravates cardiac remodeling in hypertension.

Cardiac ANG II does not alter heart size or cardiac functions when hemodynamic loading conditions remain unchanged, however, in animals with hypertension, cardiac ANG II enhances inflammation, oxidative stress, and cell death (most likely via downregulation of PI 3-kinase and Akt), contributing to cardiac hypertrophy and fibrosis.

Diabetic cardiomyopathy--a distinct disease?

Aldosterone promotes atrial fibrillation.

Aldosterone causes a substrate for atrial arrhythmias characterized by atrial fibrosis, myocyte hypertrophy, and conduction disturbances, which may have therapeutical impact for primary and secondary prevention of AF.

Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction.

This review presents short- and long-term features of post-MI in human hearts and animal models, and indicates that blunting of this innate immune cardiomyocyte response may offer new hope for the management of HF.

Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling

Inactivation of both Smad3 and nuclear factor &kgr;B/p65 signaling pathways was a key mechanism by which Smad 3 KO mice were protected from angiotensin II–mediated hypertensive cardiac remodeling.



Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?

  • M. Böhm
  • Medicine, Biology
    The American journal of cardiology
  • 2007

Treatment of heart failure with ACE inhibitors and beta-blockers

Patients with CHF generally receive a number of other drugs, which include diuretics, digoxin, vasodilators, anti-arrhythmic drugs, anticoagulants, and more recently statins, but none of them has been overall shown to improve outcome.

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

Ramipril significantly reduces the rate of development of heart failure in patients at high risk of cardiovascular events.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.